VATTEN PHARMA & FasterCapital Equitypilot Partnership Accelerates CBD Nanotech to Latin American Medical Markets
SÃO PAULO, Brazil & Dubai, UAE – Nov. 27, 2025
VATTEN PHARMA and FasterCapital today announced a strategic
partnership through FasterCapital’s Equitypilot program to accelerate
commercialization of VATTEN’s water‑soluble CBD nanotechnology
across Latin America. The collaboration pairs FasterCapital’s global
acceleration, capital and network with VATTEN’s pharmaceutical R&D,
regulatory roadmap and clinical ambitions.
Market opportunity & problem statement
The global medicinal CBD market is rapidly expanding, with Latin
America underpenetrated due to quality, dosing variability and physician
reluctance. In Brazil and broader LATAM, patients pay premium prices for
inconsistent, artisanal products and prescribers (70% reported
information gaps) cite contamination and dosing concerns. VATTEN
addresses this white space: a pharmaceutical-grade, hydrosoluble CBD
offering improved bioavailability and medical credibility where demand,
regulatory clarity and import growth converge.
Startup solution & differentiation
VATTEN PHARMA’s Ultra CBD uses nanotech to deliver up to 10x
greater absorption versus conventional oils, enabling lower doses,
improved safety and consistent pharmacology. Built on pharmaceutical
manufacturing controls, purity certification and a scientific evidence
program, VATTEN targets prescriber trust through physician education,
clinical studies and partnerships with centers of excellence. Initial go-to
market leverages U.S. inventory and phased Brazilian manufacturing —
with product lines spanning medical, veterinary and cosmetic segments
and a prioritized launch in clinical channels.
FasterCapital partnership value
Through Equitypilot, FasterCapital provides structured seed capital,
mentorship, go‑to‑market support, regulatory strategy, investor
introductions and access to commercialization partners. FasterCapital’s
selective criteria prioritize startups with defensible IP, regulatory pathways
and scalable models; VATTEN passed these filters based on clinical
focus, technology novelty and LATAM market fit. The partnership targets
key milestones: Phase‑2 manufacturing set‑up (2025), Phase‑3 clinical
evidence and Brazilian registration (2026) and expanded regional
launches.
Executive quotes
“[VATTEN PHARMA] represents the kind of deep‑tech, Nanotech, clinically focused
company we seek to accelerate — strong science, clear regulatory
pathway and high market need,” said Hesham Zreik, founding investor
and advisor at FasterCapital. “Our Equitypilot resources will compress
time to market and de‑risk early commercialization.”
“Physicians and patients need reliable, pharmaceutical‑grade CBD
options backed by evidence. FasterCapital’s capital and network let us
scale manufacturing, advance clinical trials and build the educational
programs prescribers demand,” said the CEO of VATTEN PHARMA.
“This partnership validates our approach and accelerates access to safer,
more effective treatments.”
Growth trajectory & near-term roadmap
Near term VATTEN will finalize Brazilian manufacturing plans, deploy a
specialized medical sales force, and initiate Phase‑3 clinical studies while
expanding U.S. and EU online sales. Funding rounds guided by
FasterCapital will support R&D, regulatory filings, and market rollouts to
Mexico and LATAM. Long‑term, VATTEN aims to be a market leader in
pharmaceutical CBD formulations and to broaden its pipeline into
adjacent CNS and pain indications.
